Jump to content


Photo

Dasatinib Discontinuation After 1 Year Feasible in Certain Patients With CML


  • Please log in to reply
11 replies to this topic

#1 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 23 November 2015 - 07:11 PM

Because first-line imatinib/Gleevec can be successfully discontinued in patients with CML after deep molecular response has been sustained for at least 2 years, researchers in Japan sought to evaluate the safety and efficacy of discontinuing second-line or subsequent dasatinib/Sprycel after at least 1 year of deep molecular response.

 

http://www.cancerthe...article/452873/

 

from an initial 63
after 6 months, 49% (31) treatment free
after 20 months, 47.6% (30) still treatment free
 
After cessation, studies show that if you remain CMR through the first six months, the odds of remaining CMR are definitely in your favor.
 
it's basically a 50-50 shot in getting through the first six months. 

For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt


#2 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 23 November 2015 - 08:48 PM

 

From what I've seen, there doesn't appear to be much of a difference around 50%, measured at 6 months, despite the many factors that can be added in. i.e .. duration of PCRU, medication, dosage, etc.. with Sprycel and Tasigna having a higher efficacy than Gleevec.  

 

Feel free to post stats and links

 


For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt


#3 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 25 November 2015 - 04:41 PM

half of the patients were previously treated with IFN leading to a non-homogenous cohort of patients
80% of relapses (relapse being loss of MMR) occurred in the first 3 months
39 of 100 (39%) remained treatment free 

 

STIM1 UPDATE http://bit.ly/2dLdBJe
100 CML patients who had a sustained PCRU (UMRD) for at least 2 years started the STIM study.  Only 16 maintained continuous PCRU all six years.  Another 23 never lost MMR but lost PCRU.  So 39 remained treatment free for all six years. 
Long-term followup http://bit.ly/2gdBhZL
 
treated only with imatinib; MR4.5 DMR of at least 2 years duration;. median age 61, 62 men. 62 women 
76 of 124 (61%) remained treatment free ... However 41 experienced a BCR-ABL RQ-PCR fluctuation without clear molecular relapse. In this so-called-fluctuation group of patients, 7 were found positive once, 6 twice, 12 patients between 3 and 5 times, 10 patients between 6 and 10 times and 6 patients more than 10 times confirming that BCR-ABL reappearance does not mean automatically clinical relapse.
 
Twister http://bit.ly/1kU7zre 2013
half of the patients were previously treated with IFN leading to a non-homogenous cohort of patients.
a minimum of 3 years of imatinib and a minimum of 2 years of UMRD
a prospective study of 40 patients with UMRD by using a qRT-PCR assay with a sensitivity of 4.5 log.
18 of 40 (45%) remained treatment free
 
European Stop Tyrosine Kinase Inhibitor study (EURO-SKI) first 200 http://bit.ly/1jkoEc8 2012
The 200 patients on EURO-SKI had a median treatment duration of 8 years (range 3-13 years), and 5 years of MR4 before stopping TKI (range 1-12 years).
111 of the 200 patients (56%) remained treatment free
 
EURO-SKI (for European LeukemiaNet Stop TKI) study, Part 2 http://bit.ly/238NkX3
TKI therapy was stopped in 498 people who had maintained MR4 for at least one year 
Most started treatment with Gleevec, but some had switched to Sprycel or Tasigna. The median duration of a deep molecular response (4-log reduction or better) was five years. 
Overall, 61.5% maintained good disease control for six months after stopping treatment. However, the amount of time previously spent on treatment appeared to make a difference.
Among those on a TKI for eight years or more, only 26% lost their major molecular response (MMR) within six months of stopping treatment, compared to 47% of those on a TKI for fewer than eight years.
The duration of a deep molecular response was also important. Loss of MMR was 32% in those with a sustained 4-log reduction for more than five years, compared to 46% for those with a 4-log reduction for a shorter time.
 
EURO-SKI (for European LeukemiaNet Stop TKI) study, Part 3 http://wb.md/28Ai4UM
The 868 study participants were in the chronic phase of CML, had received TKI treatment for at least 3 years, and had achieved a deep molecular response for at least 1 year. The median time from the diagnosis of CML to the first day of stopping TKI therapy was 7.7 years (range, 3.1 - 22.6 years), and the median duration of molecular remission prior to stopping TKIs was 4.7 years (range, 1.0 - 13.3 years).
Patients had a median age at diagnosis of 51.9 years, and median age at the discontinuation of TKIs was 60.3 years.
390 patients had been pretreated with hydroxyurea prior to TKI therapy, and 87 patients received interferon before TKI.
At a median follow-up of 10 months, 62% of patients continued to have deep molecular remission 6 months after discontinuing TKI therapy. At 12 months, 56% still had deep remission, as did 52% at 24 months and 49% at 36 months.
Of the 348 patients who did have molecular relapse, 37% relapsed 6 months after TKI discontinuation, 43% relapsed at 12 months, 47% relapsed at 24 months, and 50% relapsed at 36 months. Five patients died in remission.
Of patients who resumed TKI treatment, the median time for restarting was 4.1 months, and the therapy appears to be effective in those patients, despite the interruption.
In terms of duration of treatment, the rate of molecular relapse-free survival at 6 months was 65.5% in patients treated with imatinib for at least 5.8 years and 42.6% for those treated with the drug for 5.8 years or less.

 

The ISAV (for Imatinib Suspension And Validation) study http://bit.ly/1UWAZ78
was conducted in five countries (including Canada) and used a new digital PCR test which is reportedly 100-fold more sensitive than conventional PCR testing (Mori and colleagues. ASH 2014; abstract 813).
The 112 people enrolled in the study were required to be in CMR for at least 18 months. The median time on imatinib (Gleevec) was 8-9 years, and the median duration of CMR was 26 months. In the first 16 months off treatment, 43.5% of people relapsed, typically within the first nine months.
All of those who relapsed were able to regain MMR or CMR with two months of re-starting treatment.
In this study, the amount of time on Gleevec didn't have an impact on the risk of relapse.
However, a person's age was inversely related to the risk of relapse. Relapses occurred in 90% of people aged 45 years or younger, compared to 37.5% in those aged 45-64, and 27.5% in those aged 65 years or older.
I'm liking the odds.
 
KIDS (for Korean Imatinib Discontinuation) study http://bit.ly/1UWBONc
Data were analysed for 115 people. The median age was much younger (44 years) than in the other Stop trials.
The median time on a TKI was seven years; and the median duration of deep molecular response was 3-4 years
The estimated probability of maintaining MMR for one year off treatment was 67%.
 
STOP-2G-TKI study http://bit.ly/1NtPP2d August, 2013
52 patients required prior 2nd generation TKI treatment (Dasatinib, Nilotinib, Bosutinib) with a median of 6.5 years of TKI treatment and a median duration of MR4.5 of 2.3 years ... 
28 of 52 (54%) remained treatment free 
 
Select patients with CML may safely discontinue dasatinib http://goo.gl/4r2D6G
Dasatinib Discontinuation trial  (DADI) http://bit.ly/1Sc5e9V November 9, 2015
All 63 patients (42 male, 21 female) had been treated with imatinib before the start of the dasatinib treatments.
Median age, 59.5
from an initial 63 with confirmed deep molecular response for at least 1 year
after 6 months, 31 (49%) treatment free
after 20 months, 30 (47.6%) still treatment free
 
LAST: From December 2014 to December 2016, 208 patients were screened and 173 patients were enrolled from 14 sites in the US. The median age was 61 (range, 50-68) and 90 (52%) were females. Median duration of TKI prior to enrollment was 79 months (range, 51-117). At the time of enrollment, 60%, 23%, 15%, and 2% were on imatinib, nilotinib, dasatinib, and bosutinib respectively. With a median follow up of 12.3 months (range, 0.9-27) and a minimum follow up of 6 months for all patients remaining on study, 115 (66%) patients remain in a treatment-free remission (TFR). Of the 58 who restarted TKI, 46 patients restarted based on loss of MMR by central lab, and 12 restarted by patient choice. Of the 46 patients who restarted drug based on loss of MMR by central lab, 38 (82%) again achieved MMR by central lab, 3 withdrew consent before confirmation of MMR, 4 patients have had less than 6 months follow up, and one patient died (from causes unrelated to CML) before confirmation of MMR. PROs will be reported separately. Of note, 3 patients restarted TKI because of withdrawal syndrome. The proportion of patients who remained in TFR at 6 and 12 months is 73% (127/173) and 60% (76/127) respectively.
 
Managing chronic myeloid leukemia in the elderly with intermittent imatinib treatment http://bit.ly/1OJMAPq
 
INTERIM Confirms 5-Year Efficacy of Intermittent Imatinib in CML http://bit.ly/1PC1Di2
 
The LAST Study (Recruiting) http://1.usa.gov/1pbZ9NY
 
Summary of Stop Studies  http://bit.ly/1TR9x7S

For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt


#4 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 26 November 2015 - 01:17 AM

When to Stop Beneficial Treatment in Chronic Myeloid Leukemia https://shar.es/1ccOl6 


For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt


#5 mikefromillinois

mikefromillinois

    Advanced Member

  • Members
  • PipPipPip
  • 93 posts

Posted 26 November 2015 - 09:36 AM

When to Stop Beneficial Treatment in Chronic Myeloid Leukemia https://shar.es/1ccOl6 

Link doesn't seem to work



#6 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 26 November 2015 - 09:55 AM

Link doesn't seem to work

 

Thanks Mike, strange, the link works outside of the LLS forum, but doesn't work in this forum

When to Stop Beneficial Treatment in Chronic Myeloid Leukemia


For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt


#7 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 28 November 2015 - 09:35 AM

Comorbidities relevant to CML TKI choice common http://www.news-medi...ice-common.aspx


For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt


#8 Terran

Terran

    Advanced Member

  • Members
  • PipPipPip
  • 74 posts
  • LocationClovis CA

Posted 28 November 2015 - 11:06 AM

Thanks Buzz. Fascinating.

#9 soundoff

soundoff

    Advanced Member

  • Members
  • PipPipPip
  • 129 posts

Posted 29 November 2015 - 03:30 AM

Conclusions: 2G-TKI could be safely and successfully discontinued in CP-CML pts with long-lasting undetectable BCR-ABLtranscripts, especially in those without prior history of suboptimal response or resistance. Most of molecular relapses had an early onset and all were sensitive to 2G-TKI resumption. The recurrence of low levels of detectable residual disease below MMR after 2G-TKI withdrawal did not automatically herald CML relapse and did not preclude the possibility to remain treatment-free.

#10 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 30 November 2015 - 05:58 PM

Discovery of an embryonic switch for cancer stem cell generation http://bit.ly/1OrhEacvia 


For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt


#11 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 30 November 2015 - 06:53 PM

CML Clinical Trials Databasehttp://www.cmladvocates.net/cmltrials  

 

Clinical Trials - http://www.nationalc...clinical-trials


For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt


#12 Buzzm1

Buzzm1

    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 01 December 2015 - 12:52 PM

Researchers forge primitive human leukemia cells in lab https://shar.es/1ckRH2


For the benefit of yourself and others please add your CML history into your Signature

 

02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive

2012 PCRU, PCRU, PCRU, PCRU

2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17

 

At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  

 

In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  

 

longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.

 

Cumulative Gleevec dosage estimated at 830 grams

 

Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  

 

Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt





1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users